Phrixus Pharmaceuticals is developing Carmeseal™ (poloxamer 188 or P188) for
Duchenne muscular dystrophy and acute decompensated heart failure.

• OUR PEOPLE
  • MANAGEMENT
  • BOARD OF DIRECTORS
  • SCIENTIFIC & MEDICAL ADVISORY BOARD
• PRODUCT BACKGROUND
• INDICATIONS
• CONTACT

NEWS

Phrixus Pharmaceuticals, Inc. reports positive preclinical results in respiratory disease in Duchenne muscular dystrophy after subcutaneous delivery of Carmeseal™ at
very low doses

Results extend the utility of Carmeseal™ from cardiac disease to respiratory disease, the main cause...

read more

CLINICAL TRIALS

Phrixus has concurrence with FDA on the following:

• First clinical study under the IND in stable heart failure patients – dose escalation design
• Agreement for exploratory Duchenne muscular dystrophy study under same IND

©2010 Phrixus Pharmaceuticals Inc. All Rights Reserved

1600 Huron Parkway, Building 520, 2nd Floor, Ann Arbor, MI 48109 (734) 358-9015 thomas.collet@phrixuspharmaceuticals.com